The median overall survival was similar between the treatment arms.
Black race was significantly associated with not receiving a recommendation for chemotherapy.
The median duration of response was not reached at a median follow-up of 21 months.
The poorest neighborhoods in New York City have cervical cancer rates 73% higher than the wealthiest neighborhoods.
Patients with a positive AGO score had better survival outcomes with surgery plus chemotherapy, compared with chemotherapy alone.
Reductions in cervical cancer incidence and mortality were greater for patients aged 15-24 years than for those aged 25-39 years.
Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions.
The median PFS was 56.0 months with olaparib and 13.8 months with placebo.
Unemployed adults were less likely to be up to date on screening for cervical, breast, colorectal, and prostate cancer.
There were 448 fewer cervical cancers and 17,235 fewer CIN3 cases than expected.
Gemogenovatucel-T improved recurrence-free and overall survival at 3 years.
TP53 CHIP variants were significantly more common in patients with therapy-related myeloid neoplasms.
Changes in weight and BMI were associated with disease-free and overall survival.
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Patients treated at facilities with a high use of neoadjuvant chemotherapy had greater declines in 1-year mortality rates over time.
Higher rates of infection-related cancers were seen among Hispanic individuals.
The duration of response was more than 3 years in 68% of patients.
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 women with recurrent or metastatic cervical cancer.
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.